Richárd Márkus

1.6k total citations
30 papers, 1.2k citations indexed

About

Richárd Márkus is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Richárd Márkus has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Immunology and 10 papers in Oncology. Recurrent topics in Richárd Márkus's work include Biosimilars and Bioanalytical Methods (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Prostate Cancer Treatment and Research (7 papers). Richárd Márkus is often cited by papers focused on Biosimilars and Bioanalytical Methods (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Prostate Cancer Treatment and Research (7 papers). Richárd Márkus collaborates with scholars based in United States, Switzerland and Canada. Richárd Márkus's co-authors include Vincent Chow, Primal Kaur, Guozhi Gao, Beth Barber, Tomáš Skácel, Karim Fizazi, Linda D. Bosserman, Maureen J. Lage, Kathleen M. Fox and John M. Brooks and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PEDIATRICS.

In The Last Decade

Richárd Márkus

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richárd Márkus United States 15 417 322 267 266 207 30 1.2k
Chuanbo Zang United States 11 386 0.9× 165 0.5× 210 0.8× 95 0.4× 228 1.1× 42 1.3k
A.B. Gottlieb United States 9 1.1k 2.7× 98 0.3× 175 0.7× 32 0.1× 38 0.2× 35 1.4k
Sergio Schwartzman United States 21 548 1.3× 98 0.3× 71 0.3× 44 0.2× 30 0.1× 59 1.4k
Florence Ida Hsu United States 11 269 0.6× 119 0.4× 234 0.9× 100 0.4× 138 0.7× 26 985
Ieuan Jones United Kingdom 13 223 0.5× 40 0.1× 308 1.2× 171 0.6× 206 1.0× 29 1.0k
J. R. Kalden Germany 19 732 1.8× 127 0.4× 86 0.3× 78 0.3× 75 0.4× 57 1.7k
Christopher S. Awtrey United States 16 112 0.3× 229 0.7× 93 0.3× 96 0.4× 25 0.1× 31 1.3k
Takaaki Konishi Japan 14 105 0.3× 277 0.9× 53 0.2× 236 0.9× 81 0.4× 101 853
M. Lange United States 6 574 1.4× 181 0.6× 36 0.1× 36 0.1× 23 0.1× 7 2.2k
Sébastien Viatte United Kingdom 19 640 1.5× 161 0.5× 155 0.6× 282 1.1× 14 0.1× 54 1.7k

Countries citing papers authored by Richárd Márkus

Since Specialization
Citations

This map shows the geographic impact of Richárd Márkus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richárd Márkus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richárd Márkus more than expected).

Fields of papers citing papers by Richárd Márkus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richárd Márkus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richárd Márkus. The network helps show where Richárd Márkus may publish in the future.

Co-authorship network of co-authors of Richárd Márkus

This figure shows the co-authorship network connecting the top 25 collaborators of Richárd Márkus. A scholar is included among the top collaborators of Richárd Márkus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richárd Márkus. Richárd Márkus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Márkus, Richárd, Helen J. McBride, Monica Ramchandani, et al.. (2019). A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501. Advances in Therapy. 36(8). 1833–1850. 24 indexed citations
2.
Hanes, Vladimir, Vincent Chow, Zhiying Pan, & Richárd Márkus. (2018). A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemotherapy and Pharmacology. 82(5). 899–905. 16 indexed citations
3.
Márkus, Richárd, Vincent Chow, Zhiying Pan, & Vladimir Hanes. (2017). A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemotherapy and Pharmacology. 80(4). 755–763. 36 indexed citations
4.
Hanes, Vladimir, Vincent Chow, Nan Zhang, & Richárd Márkus. (2017). A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemotherapy and Pharmacology. 79(5). 881–888. 32 indexed citations
5.
6.
Kaur, Primal, Vincent Chow, Nan Zhang, et al.. (2016). A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Annals of the Rheumatic Diseases. 76(3). 526–533. 65 indexed citations
7.
Márkus, Richárd, Primal Kaur, Vincent Chow, et al.. (2015). Results of functional testing and pharmacokinetics comparing ABP 215 to bevacizumab.. Journal of Clinical Oncology. 33(3_suppl). 711–711. 6 indexed citations
8.
Márkus, Richárd, Teresa L. Born, Vincent Chow, et al.. (2015). Functional similarity and human pharmacokinetic (PK) equivalence of ABP 215 and bevacizumab.. Journal of Clinical Oncology. 33(15_suppl). e14659–e14659. 4 indexed citations
9.
10.
Dodds, Mike, Vincent Chow, Richárd Márkus, et al.. (2013). The Use of Pharmacometrics to Optimize Biosimilar Development. Journal of Pharmaceutical Sciences. 102(11). 3908–3914. 5 indexed citations
11.
Fox, Kathleen M., John M. Brooks, Shravanthi R. Gandra, Richárd Márkus, & Chiun‐Fang Chiou. (2009). Estimation of Cachexia among Cancer Patients Based on Four Definitions. Journal of Oncology. 2009. 1–7. 110 indexed citations
12.
Cetin, Karynsa, Jennifer Beebe‐Dimmer, Jon P. Fryzek, Richárd Márkus, & Michael A. Carducci. (2009). Recent Time Trends in the Epidemiology of Stage IV Prostate Cancer in the United States: Analysis of Data From the Surveillance, Epidemiology, and End Results Program*. Urology. 75(6). 1396–1404. 31 indexed citations
13.
Senti, Gabriela, Bettina M. Prinz Vavricka, Richárd Márkus, et al.. (2008). Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences. 105(46). 17908–17912. 254 indexed citations
14.
Saad, Fred, Richárd Márkus, & Carsten Goessl. (2007). Targeting the receptor activator of nuclear factor‐κB (RANK) ligand in prostate cancer bone metastases. British Journal of Urology. 101(9). 1071–1075. 22 indexed citations
15.
Lage, Maureen J., Beth Barber, & Richárd Márkus. (2007). Association Between Androgen-Deprivation Therapy and Incidence of Diabetes Among Males with Prostate Cancer. Urology. 70(6). 1104–1108. 76 indexed citations
16.
Karácsony, Péter, et al.. (2007). The comparative study of wheat growing results in Hungary and Austria. AgEcon Search (University of Minnesota, USA). 49(1). 1–59.
17.
18.
Gibson, Ronald L., George Retsch‐Bogart, Christopher M. Oermann, et al.. (2006). Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology. 41(7). 656–665. 89 indexed citations
19.
Márkus, Richárd, et al.. (1995). An alternative approach to the optimal design of an LD50 bioassay. Statistics in Medicine. 14(8). 841–852. 13 indexed citations
20.
Márkus, Richárd. (1967). Ostwald's relative forest rent theory.. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chuanbo Zang Breakdown of academic impact, for papers by A.B. Gottlieb Breakdown of academic impact, for papers by Sergio Schwartzman Breakdown of academic impact, for papers by Florence Ida Hsu Breakdown of academic impact, for papers by Ieuan Jones Breakdown of academic impact, for papers by J. R. Kalden Breakdown of academic impact, for papers by Christopher S. Awtrey Breakdown of academic impact, for papers by Takaaki Konishi Breakdown of academic impact, for papers by M. Lange Breakdown of academic impact, for papers by Sébastien Viatte
Rankless by CCL
2026